Journal of Surgery Concepts & Practice >

2025 , Vol. 30 >Issue 06: 529 - 536

DOI: https://doi.org/10.16139/j.1007-9610.2025.06.12

Review

Research progress on the mechanism of regulated cell death in thyroid carcinoma

  • NIU Lingshan ,
  • ZHAO Yue ,
  • SHI Xu ,
  • YANG Zheyu ,
  • PAN Ruijun ,
  • CAI Wei
Expand
  • Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2025-03-13

  Online published: 2026-01-26

Fold

Abstract

Thyroid carcinoma is one of the malignant tumors with rapidly increasing incidence rates. Some refractory patients face challenges from drug toxicity and resistance, urgently requiring the discovery of new therapeutic pathways to improve prognosis. Regulatory cell death（RCD）is a highly regulated orderly death mode, including apoptosis, necroptosis, pyroptosis, ferroptosis, and cuproptosis. Recent studies have found that RCD is closely associated with tumor progression, invasion, and resistance. This article systematically reviewed various death modes in thyroid cancer, including the core signaling nodes of each death pathway, and explored their specific functions in tumor progression. It also summarized potential therapeutic strategies targeting these death pathways. However, the complexity of RCD mechanisms and the sensitivity of treatments remain controversial. Future efforts should focus on screening broad-spectrum targets and developing synergistic therapies to ultimately achieve precise treatment based on cell death, thereby improving the prognosis of refractory thyroid cancer.

Key words： Thyroid carcinoma; Regulated cell death(RCD); Targeted therapy; Drug resistance mechanism; Combination therapy

Cite this article

NIU Lingshan , ZHAO Yue , SHI Xu , YANG Zheyu , PAN Ruijun , CAI Wei . Research progress on the mechanism of regulated cell death in thyroid carcinoma[J]. Journal of Surgery Concepts & Practice, 2025 , 30(06) : 529 -536 . DOI: 10.16139/j.1007-9610.2025.06.12

References

[1] BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263.
[2] HAN B, ZHENG R, ZENG H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1):47-53.
[3] CHEN D W, LANG B H H, MCLEOD D S A, et al. Thyroid cancer[J]. Lancet, 2023, 401(10387):1531-1544.
[4] SUBBIAH V, HU M I, WIRTH L J, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study[J]. Lancet Diabetes Endocrinol, 2021, 9(8):491-501.
[5] WIRTH L J, SHERMAN E, ROBINSON B, et al. Efficacy of selpercatinib in RET-altered thyroid cancers[J]. N Engl J Med, 2020, 383(9):825-835.
[6] TANG D, KANG R, BERGHE T V, et al. The molecular machinery of regulated cell death[J]. Cell Res, 2019, 29(5):347-364.
[7] LIU J, KUANG F, KROEMER G, et al. Autophagy-dependent ferroptosis: machinery and regulation[J]. Cell Chem Biol, 2020, 27(4):420-435.
[8] CZABOTAR P E, LESSENE G, STRASSER A, et al. Control of apoptosis by the BCL-2 protein family[J]. Nat Rev Mol Cell Biol, 2014, 15(1):49-63.
[9] TABAS I, RON D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress[J]. Nat Cell Biol, 2011, 13(3):184-190.
[10] HETZ C, ZHANG K, KAUFMAN R J. Mechanisms, regulation and functions of the unfolded protein response[J]. Nat Rev Mol Cell Biol, 2020, 21(8):421-438.
[11] KISCHKEL F C, HELLBARDT S, BEHRMANN I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor[J]. EMBO J, 1995, 14(22):5579-5588.
[12] LI H, ZHU H, XU C J, et al. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis[J]. Cell, 1998, 94(4):491-501.
[13] SOMNAY Y R, YU X M, LLOYD R V, et al. Notch3 expression correlates with thyroid cancer differentiation, induces apoptosis, and predicts disease prognosis[J]. Cancer, 2017, 123(5):769-782.
[14] XIONG H, YU J, JIA G, et al. Emerging roles of circUBAP2 targeting miR-370-3p in proliferation, apoptosis, and invasion of papillary thyroid cancer cells[J]. Hum Cell, 2021, 34(6):1866-1877.
[15] FU S, ZHAO N, JING G, et al. Matrine induces papillary thyroid cancer cell apoptosis in vitro and suppresses tumor growth in vivo by downregulating miR-182-5p[J]. Biomed Pharmacother, 2020, 128:110327.
[16] GUNDA V, SAROSIEK K A, BRAUNER E, et al. Inhibition of MAPKinase pathway sensitizes thyroid cancer cells to ABT-737 induced apoptosis[J]. Cancer Lett, 2017, 395:1-10.
[17] STUCKEY D W, SHAH K. TRAIL on trial: preclinical advances in cancer therapy[J]. Trends Mol Med, 2013, 19(11):685-694.
[18] FULDA S, VUCIC D. Targeting IAP proteins for therapeutic intervention in cancer[J]. Nat Rev Drug Discov, 2012, 11(2):109-124.
[19] WEST A C, JOHNSTONE R W. New and emerging HDAC inhibitors for cancer treatment[J]. J Clin Invest, 2014, 124(1):30-39.
[20] TORTI S V, TORTI F M. Iron and cancer: more ore to be mined[J]. Nat Rev Cancer, 2013, 13(5):342-355.
[21] JIANG L, KON N, LI T, et al. Ferroptosis as a p53-mediated activity during tumour suppression[J]. Nature, 2015, 520(7545):57-62.
[22] SUN X, OU Z, CHEN R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells[J]. Hepatology, 2016, 63(1):173-184.
[23] WANG H H, MA J N, ZHAN X R. Circular RNA circ_0067934 attenuates ferroptosis of thyroid cancer cells by miR-545-3p/SLC7A11 signaling[J]. Front Endocrinol (Lausanne), 2021, 12:670031.
[24] SIRAJ A K, PARVATHAREDDY S K, PRATHEESHKUMAR P, et al. PD-L1 is an independent prognostic marker in middle eastern PTC and its expression is upregulated by BRAFV600E mutation[J]. Cancers (Basel), 2021, 13(3):555.
[25] 董佳悦, 李树杰, 王艳, 等. 双氢青蒿素和索拉非尼诱导未分化甲状腺癌铁死亡的协同机制[J]. 中华内分泌代谢杂志, 2023, 39(7):596-604.
  DONG J Y, LI S J, WANG Y, et al. Synergistic mechanism of dihydroartemisinin and sorafenib in inducing ferroptosis in undifferentiated thyroid carcinoma[J]. Chin J Endocrinol Metabolism, 2023, 39(7):596-604.
[26] RENAUD C O, ZIROS P G, CHARTOUMPEKIS D V, et al. Keap1/Nrf2 signaling: a new player in thyroid pathophysiology and thyroid cancer[J]. Front Endocrinol (Lausanne), 2019, 10:510.
[27] CHEN H, LI Z, XU J, et al. Curcumin induces ferroptosis in follicular thyroid cancer by upregulating HO-1 expression[J]. Oxid Med Cell Longev, 2023, 2023:6896790.
[28] WANG X, XU S, ZHANG L, et al. Vitamin C induces ferroptosis in anaplastic thyroid cancer cells by ferritinophagy activation[J]. Biochem Biophys Res Commun, 2021, 551:46-53.
[29] GUO Y, LIANG J, DING L, et al. The endoplasmic reticulum stress-ferroptosis reciprocal signaling orchestrates anti-tumor effect of anlotinib in anaplastic thyroid cancer[J]. Cancer Cell Int, 2025, 25(1):310.
[30] JIANG M, QI L, LI L, et al. The caspase-3/GSDME signal pathway as a switch between apoptosis and pyroptosis in cancer[J]. Cell Death Discov, 2020, 6:112.
[31] LI F, DU R, KOU J, et al. Elucidating the role of pyroptosis in papillary thyroid cancer: prognostic, immunological, and therapeutic perspectives[J]. Cancer Cell Int, 2024, 24(1):45.
[32] ZHAO Q, FENG H, YANG Z, et al. The central role of a two-way positive feedback pathway in molecular targeted therapies-mediated pyroptosis in anaplastic thyroid cancer[J]. Clin Transl Med, 2022, 12(2):e727.
[33] ZHANG L, JIANG Y H, FAN C, et al. MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis[J]. Biomed Pharmacother, 2021, 143:112133.
[34] BOURNE C M, TAABAZUING C Y. Harnessing pyroptosis for cancer immunotherapy[J]. Cells, 2024, 13(4):346.
[35] CHEN L, MIN J, WANG F. Copper homeostasis and cuproptosis in health and disease[J]. Signal Transduct Target Ther, 2022, 7(1):378.
[36] SHI Y, SHENG P, GUO M, et al. Cuproptosis-related lncRNAs predict prognosis and immune response of thyroid carcinoma[J]. Front Genet, 2023, 14:1100909.
[37] HUANG J, SHI J, WU P, et al. Identification of a novel cuproptosis-related gene signature and integrative analyses in thyroid cancer[J]. J Clin Med, 2023, 12(5):2014.
[38] CHEN Y G, LIU H X, HONG Y, et al. PCNP is a novel regulator of proliferation, migration, and invasion in human thyroid cancer[J]. Int J Biol Sci, 2022, 18(9):3605-3620.
[39] YANG Z, HUANG R, WEI X, et al. The SIRT6-autophagy-warburg effect axis in papillary thyroid cancer[J]. Front Oncol, 2020, 10:1265.
[40] WU J, LIANG J, LIU R, et al. Autophagic blockade potentiates anlotinib-mediated ferroptosis in anaplastic thyroid cancer[J]. Endocr Relat Cancer, 2023, 30(9):e230036.
[41] WANG W, KANG H, ZHAO Y, et al. Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib[J]. J Clin Endocrinol Metab, 2017, 102(2):634-643.
[42] WANG Z, WU P, SHI J, et al. A novel necroptosis-related gene signature associated with immune landscape for predicting the prognosis of papillary thyroid cancer[J]. Front Genet, 2022, 13:947216.
[43] LI Y, WU D. Identification of signature genes and immune infiltration analysis in thyroid cancer based on PANoptosis related genes[J]. Front Endocrinol (Lausanne), 2024, 15:1397794.
[44] XIE D, HUANG L, LI C, et al. Identification of PANoptosis-related genes as prognostic indicators of thyroid cancer[J]. Heliyon, 2024, 10(11):e31707.
[45] GUO Y W, ZHU L, DUAN Y T, et al. Ruxolitinib induces apoptosis and pyroptosis of anaplastic thyroid cancer via the transcriptional inhibition of DRP1-mediated mitochondrial fission[J]. Cell Death Dis, 2024, 15(2):125.
[46] BROECKER-PREUSS M, VIEHOF J, JASTROW H, et al. Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cells[J]. J Exp Clin Cancer Res, 2015, 34(1):69.
Options
Outlines

/

〈 〉